Wayne Kuznar | Authors


HPV16+ HNSCC Response to PDS0101 Plus Pembrolizumab in VERSATILE-002

June 08, 2022

In CPI-naïve, HPV16-positive, CPS-positive patients, PDS0101 plus pembrolizumab exhibits preliminary evidence of clinical benefit in a majority of patients with an acceptable safety profile and allows continued dosing of pembrolizumab.

Doublet Therapy Shows Better Response Vs Chemotherapy in BRAF V600+ Pediatric Low-Grade Glioma

June 08, 2022

According to Eric Bouffet, MD, results from a phase 2 study presented during the 2022 ASCO Annual Meeting show how important it is to document as early as possible the molecular alterations that are present in this type of tumor.

Tafasitamab Plus Lenalidomide Bests Standard Treatments in Key High-Risk R/R DLBCL Subgroups

June 06, 2022

According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.